Anticonvulsive drugs. Are they useful in the treatment and prevention of bipolar disorders?;Antikonvulsiva. Stellenwert in der behandlung und prävention von bipolaren störungen

Krankenhauspsychiatrie

Volumn 13, Issue SUPPL. 1, 2002, Pages

  Dobmeier, M ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

Anticonvulsive drugs; Bipolar disorder; Combination therapy

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ERGENYL CHRONO; GABAPENTIN; LAMOTRIGINE; LITHIUM; OXCARBAZEPINE; PHENYTOIN; QUILONIUM; TIAGABINE; TOPIRAMATE; VALPROIC ACID;

ARTICLE; DISEASE SEVERITY; DRUG EFFICACY; HUMAN; MANIC DEPRESSIVE PSYCHOSIS; MEDICAL DECISION MAKING; MENTAL PATIENT; SIDE EFFECT;

EID: 0036750212     PISSN: 0937289X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Ahrens B, Müller-Oerlinghausen B, Schou M et al. Excess cardiovascular and suicide Mortality of affective disorders may be reduced by lithium prophylaxis. J Affect. Disord 1995; 33: 67-75
2. Beghi E, DiMascio R, Sasanelli F et al. Advers reactions to antiepileptic drugs: a multicenter survey of clinical pratice. Epilepsia 1986; 27: 323-330
3. Bowden CL, Brugger AM, Swann AC et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA 1994; 271: 918-924
4. Bowden CL. Role of newer medications for bipolar disorder. J Clin Psychopharmacol 1996; 16 (2 Suppl 1): 48-55
5. Bowden CL, Calabrese JR, McElroy SL, Gyulai L, Wassef A, Petty F, Pope AC, Chou JC, Keck PE, Rhodes LJ, Swann AC, Hirschfeld RM, Wosniak PJ. A randomized, placebo-controlled 12-month trial of divalproex and lithium in the treatment of out-patients of bipolar I disorder. Arch Gen Psychiatry 2000; 57: 481-489
6. Brennan MJW, Sandyk R, Borsook D. Use of sodium valproat in the management of affective disorders: basic and clinical aspects. In: Emerich HM, Okuma T, Müller AA (ed.). Anticonvulsants in Affective Disorders. Amsterdam, Netherlands: Excerpta Medica, 1984: 56-65
7. Cade JFJ. Lithium salts in the treatment of psychotic exitement. Med J Aust 1949; 36: 349-352
8. Calabrese JR, Shelton MD, Rapport DJ, Kimmel SE. Bipolar disorders and the effectiveness of novel anticonvulsants. J Clin Psychiatry 2002; 63 (Suppl 3): 5-9
9. Dobmeier M, Franke C, Wolfersdorf M für die AMÜP Bayern. Psychopharmaka zur Behandlung der Manie: Ein Ergebnis der Stichtagserhebung des AMÜP Projektes Bayern. Psychopharmakotherapie 2000; 3: 130-135
10. Dobmeier M, Franke C, Wolfersdorf M für die AMÜP Bayern. Indikationen und unerwünschte Arzneimittelwirkungen von Antiepileptika im psychiatrischen Einsatz: AMÜP Bayern Ergebnisse. Psychopharmakotherapie 2001; 8: 23-27
11. Dubovsky SL, Buzan RD. Novel alternatives and supplements to Lithium and anticonvulsants for bipolar affective disorder. J Clin Psychiatry 1997; 58: 224-242
12. Emerich HM, Dose M, von Zerssen D. The use of sodium valproat, carbamazepine, and oxcarbamazepine in patients with affective disorders. J Affect Disord 1985; 8: 243-250
13. Emerich HM, Dose M, Stoll KD. Die Behandlung von affektiven Psychosen mit Antikonvulsiva. Münch Med Wochenschr 1990; 132: 65-70
14. Emerich HM, Dose M. Carbamazepin und andere Antikonvulsiva. In: Riederer P, Laux G, Pöldinger W. Neuro-Psychopharmakologie. Band 3. Wien: Springer-Verlag, 1993: 529-555
15. Freeman TW, Clothier JL, Pazzaglia P et al. A double-blind comparison of valproat and lithium in the treatment of acute mania. Am J Psychiatry 1992: 149: 108-111
16. Freeman MP, Stoll AL. Modd stabilizer combinations: a review of safety and efficacy. Am J Psychiatry 1998; 155: 12-21
17. Gelenberg AJ, Hopkins HS. Antipsychotics in Bipolar Disorder. J Clin Psychiatry 1996; 75 (Suppl 9): 49-52
18. Greil W, Kleindienst N, Erazo N, Müller-Oerlinghausen B. Differential respones to lithium and carbamazepin in the prophylaxis of bipolar disorder. J Clin Psychopharmacol 1999; 18: 283-285
19. Keck PE, McElroy SL, Nemeroff CB. Anticonvulsants in the treatment of bipolar disorder. The Journal of Neuropsychiatry and Clinical Neurosiences 1992; 4: 395-405
20. Keck PE, McElroy SL. Outcome in the pharmacologic treatment of bipolar disorder. J Clin Psychopharmacol 1996; 16: 15-23
21. Kishimoto A, Omura F, Inoue K, Tsutsui T, Okazaki T, Hazama H. A comparative study of carbamazepine and lithium for prophilaxis of bipolar affektive disorder. Clin Pharmacol Ther 1984; 35 (2): 251
22. Obrocea GV, Dunn RM, Frye MA, Ketter TA, Luckenbaugh DA, Leverich GS, Speer AM, Osuch EA, Jajodia K, Post RM. Clinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disorders. Biol Psychiatry 2002; 51 (3): 253-260
23. Placidi GF, Lenzi A, Lazzerini F, Cassano GB, Akiskal HS. The comparative efficacy and safety of carbamazepine versus lithium: a randomized double blind 3 year trial in 83 patients. J Clin Psychiatry 1986; 47: 490-494
24. Schou M. Lithium treatment at 52. J Affect Disord 2001; 67: 21-32
25. Vestergaard P, Poulstrup I, Schou M. Prospective studies in a Lithium cohort. Tremor, weight gain, diarrhea, psychological complaints. Acta Psychiatr Scand 1988; 78: 434-441
26. Watkins SE, Callender K, Thomas DR. The effect of carbamazepine and lithium on remision from affective illness. Br J Psychiatry 1987; 150: 180-182